Hepatocellular Adenoma Update: Diagnosis, molecular Classification, and Clinical Course
Sarah Poetter-Lang,Ahmed Ba-Ssalamah,Nina Bastati,Sami A Ba-Ssalamah,Jacqueline C Hodge,Giuseppe Brancatelli,Valérie Paradis,Valérie Vilgrain
DOI: https://doi.org/10.1093/bjr/tqae180
2024-09-05
Abstract:Hepatocellular adenomas (HCA) are acquired focal liver lesions, usually 3-5 cm, that occur mainly in young-to-middle-aged women who are on long-term estrogen-containing contraceptives or young men after prolonged use of anabolic steroids. Furthermore, distinct underlying diseases, such as obesity, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), glycogen storage disease, etc are considered risk factors. Adenomatosis is when ≥ 10 adenomas occur simultaneously. Histologically, HCAs consist of hepatocytes arranged in strands without bile ducts or portal veins and are supplied only arterially. The 2017 Bordeaux classification, in particular Nault et al., divided HCAs into eight subtypes according to their pheno- and genotypic characteristics. This includes HCAs with hepatocyte-nuclear-factor (HNF1-alpha mutation), HCAs with β-catenin mutation, and HCAs without either of these genetic mutations, which are further subdivided into HCAs with and without inflammatory cells.[1] HCAs should no longer be classified as purely benign without histologic workup since three of the eight subtypes are considered high-risk lesions, requiring adequate management: malignant transformation of the pure (ßex3-HCA) and mixed inflammatory/β-catenin exon 3 (ßex3-IHCA) adenomas, as well as potential bleeding of the sonic hedgehog HCA (sh-HCA) and pure (ßex7/8-HCA) and mixed inflammatory/β-catenin exon 7/8 (ßex7/8-IHCA). Elective surgery is recommended for any HCA in a male, or for any HCA exceeding 5 cm. Although MRI can classify up to 80% of adenomas, if findings are equivocal, biopsy remains the reference standard for adenoma subtype.